A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

602

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

February 28, 2013

Study Completion Date

August 31, 2015

Conditions
Breast Cancer
Interventions
DRUG

Trastuzumab emtansine

The dose was calculated based on the patient's Baseline weight on Day 1 of each 3-week treatment cycle. The same dose was administered in subsequent cycles if the patient's weight stayed within 10% of the Baseline weight. If there was a weight change \> 10%, the dose was adjusted accordingly and the recorded weight became the new Baseline weight. Trastuzumab emtansine was provided as a single-use lyophilized formulation.

DRUG

Treatment of physician's choice

"The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for late-line HER2-positive metastatic breast cancer treatment after receipt of both trastuzumab- and lapatinib-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone \[LHRH\] agonist) hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.~Participants who had documented progressive disease (PD) were eligible to switch treatment to receive trastuzumab emtansine 3.6 mg/kg. Participants who switched treatment remained on trastuzumab emtansine treatment until another PD event or unmanageable toxicity.~The formulation, storage, and preparation of all TPC were as per the appropriate package insert or national prescribing information."

Trial Locations (184)

1122

Budapest

1145

Budapest

2217

Kogarah

2610

Wilrijk

3000

Leuven

3010

Bern

3199

Frankston

3526

Miskolc

4101

South Brisbane

5004

Szolnok

5700

Gyula

6000

Perth

Kecskemét

6701

Szeged

8091

Zurich

10110

Bangkok

10400

Bangkok

10467

The Bronx

10700

Bangkok

11042

Lake Success

13900

Biella

14076

Caen

15009

A Coruña

16132

Genoa

19104

Philadelphia

19713

Newark

20010

Washington D.C.

20121

Milan

20132

Milan

20246

Hamburg

20817

Bethesda

21044

Columbia

22081

Hamburg

23230

Richmond

24105

Kiel

24127

Bergamo

25123

Brescia

28033

Madrid

28034

Madrid

28040

Madrid

28203

Charlotte

29010

Málaga

29414

Charleston

30008

Murcia

30060

Marietta

30559

Hanover

30900

Nîmes

31059

Toulouse

31300

Toulouse

32256

Jacksonville

33065

Coral Springs

33300

Bordeaux

33324

Plantation

33442

Deerfield Beach

33604

Bielefeld

33905

Fort Myers

34298

Montpellier

37044

Tours

37203

Nashville

37232

Nashville

37404

Chattanooga

41014

Seville

42271

Saint-Priest-en-Jarez

43219

Columbus

44124

Cona (Ferrara)

44202

Nantes

45657

Recklinghausen

46026

Valencia

46815

Fort Wayne

48013

Bilbao

48201

Detroit

49100

Petah Tikva

49933

Angers

51056

Reims

51101

Sioux City

52621

Ramat Gan

53840

Troisdorf

54290

Trier

55131

Mainz

55455

Minneapolis

60153

Maywood

60612

Chicago

60637

Chicago

63141

St Louis

67065

Strasbourg

68114

Omaha

69373

Lyon

70190

Stuttgart

71913

Hot Springs

75185

Uppsala

75231

Paris

75246

Dallas

76038

Rouen

76104

Fort Worth

78229

San Antonio

80131

Napoli

80220

Denver

80638

München

83854

Post Falls

85100

Potenza

85704

Tucson

88212

Ravensburg

90048

West Hollywood

90185

Umeå

91120

Jerusalem

92108

San Diego

92346

Highland

94080

South San Francisco

94115

San Francisco

94545

Hayward

94589

Vallejo

94596

Walnut Creek

94611

Oakland

94800

Villejuif

95051

Santa Clara

95119

San Jose

95204

Stockton

95661

Roseville

95825

Sacramento

97210

Portland

98109

Seattle

110085

New Delhi

115478

Moscow

355045

Stavropol

411004

Pune

443031

Samara

560027

Bangalore

600035

Chennai

700053

Kolkata

3109601

Hafia

6423906

Tel Aviv

7610001

Rehovot

8410101

Beersheba

06611

Trumbull

67214-3728

Wichita

04074

Scarborough

02115

Boston

02130

Boston

02215

Boston

08901

New Brunswick

41950-610

Salvador

74140-050

Goiânia

22260-020

Rio de Janeiro

90430-090

Porto Alegre

88301-220

Itajaí

01509-900

São Paulo

E1C 6Z8

Moncton

M4N 3M5

Toronto

G1S 4L8

Québec

S4T 7T1

Regina

S7N 4H4

Saskatoon

656 53

Brno

500 05

Hradec Králové

775 20

Olomouc

128 08

Prague

150 06

Prague

06189

Nice

411 001

Pune

0310

Oslo

15-027

Bialystok

85-796

Bydgoszcz

80-952

Gdansk

20-090

Lublin

61-866

Poznan

02-781

Warsaw

04001

Košice

058 01

Poprad

410-769

Kyunggi-do

110-744

Seoul

120-752

Seoul

135-170

Seoul

138-736

Seoul

08036

Barcelona

08907

Barcelona

701 85

Örebro

BN2 5BE

Brighton

GU2 7XX

Guildford

W1G 6AD

London

ME16 9QQ

Maidstone

L63 4JY

Metropolitan Borough of Wirral

NG5 1PB

Nottingham

S10 2SJ

Sheffield

ST4 6QG

Stoke-on-Trent

SS0 0RY

Westcliffe-on-sea

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01419197 - A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy | Biotech Hunter | Biotech Hunter